ArticleHuman genomics2025
Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type.
Article in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Global bibliometric analysis of TP53-mutated acute myeloid leukemia: research hotspots and evolution.Translational cancer research · 2026Article
- Construction of a predictive model based on the risk of relapse after cytarabine consolidation therapy in acute myeloid leukemia patients.The oncologist · 2026Article
- Review
- Behçet's syndrome-like features revealing myelodysplastic syndrome withFrontiers in immunology · 2026Article
- Pandora's Box of AML: HowBiomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
While variant TP53 is an adverse prognosis factor in myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML), current clinical prognosis and variation feature analysis of TP53 alterations remain limited. We evaluated 333 MDS/AML patients with TP53 mutations, single nucleotide polymorphisms (SNPs), and wild-type TP53 to characterize clinical features and identify prognostic factors using next-generation sequencing (NGS) data. Interpretation requires caution due to sample size limitations, particularly in subgroup analyses. Multivariate analysis identified age, gender, cytogenetic risk, transplantation, white blood cell (WBC) count, TP53 status, and TP53 variant allele frequency (VAF) > 40% as independent prognostic factors. Patients with TP53 mutations (n = 45) had significantly worse overall survival (OS) and disease-free survival (DFS) (2-year OS: 34.94%; DFS: 38.26%) compared to those with TP53 SNPs (n = 84; 2-year OS: 77.25%; DFS: 87.54%; P < 0.001) and TP53 wild-type patients (n = 204; 2-year OS: 63.25%; DFS: 70.72%; P < 0.05). Notably, TP53 SNP carriers exhibited comparable or superior survival to TP53 wild-type patients. Focusing on the TP53 mutated cases, we identified TET2 as a possible disadvantageous prognosis factor among the coexistent gene mutations of TP53, suggesting that a potential dual-gene (TET2-TP53) mutation signature is associated with shorter survival. Therapeutic analysis revealed that transplantation improved survival in TP53 variant patients compared to chemotherapy alone, supporting its role as an effective intervention. Our findings highlight the prognostic significance of TP53 alterations in MDS/AML and underscore the importance of karyotype risk stratification, post-transplant relapse prevention, and mutation monitoring to optimize outcomes. Future studies with larger cohorts are needed to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.